trans

More documents

Recommendations

Info

S E C T I O N III BIOCHEMISTRY AND CELL BIOLOGY HELMINTHS
This Page Intentionally Left Blank
Page 2 and 3:
Molecular Medical Parasitology
Page 4 and 5:
Molecular Medical Parasitology Edit
Page 6 and 7:
Contents List of contributors Prefa
Page 8 and 9:
List of contributors Mark Blaxter,
Page 10 and 11:
LIST OF CONTRIBUTORS ix Richard. J.
Page 12 and 13:
Preface Parasitology was born as th
Page 14 and 15:
S E C T I O N I MOLECULAR BIOLOGY
Page 16 and 17:
C H A P T E R 1 Parasite genomics M
Page 18 and 19:
TABLE 1.1 Parasite genomes: genome
Page 20 and 21:
GENERATING GENOMICS DATA 7 differen
Page 22 and 23:
GENERATING GENOMICS DATA 9 TABLE 1.
Page 24 and 25:
GENERATING GENOMICS DATA 11 called
Page 26 and 27:
GENERATING GENOMICS DATA 13 200 000
Page 28 and 29:
BIOINFORMATICS AND THE ANALYSIS OF
Page 30 and 31:
THE POST-GENOMICS ERA, AND THE OTHE
Page 32 and 33:
THE PARASITES AND THEIR GENOMES 19
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
FURTHER READING 27 treated with a d
Page 42 and 43:
C H A P T E R 2 RNA processing in p
Page 44 and 45:
TRANS-SPLICING 31 cis trans Exon 1
Page 46 and 47:
TRANS-SPLICING 33 snRNPs (small nuc
Page 48 and 49:
TRANS-SPLICING 35 trans cis U2AF35
Page 50 and 51:
RNA EDITING 37 P AAAA... AAAA... AA
Page 52 and 53:
RNA EDITING 39 entire transcript re
Page 54 and 55:
RNA EDITING 41 5 Editing block C Ed
Page 56 and 57:
RNA EDITING 43 microscopy) approach
Page 58 and 59:
FURTHER READING 45 Nilsen, T.W. (19
Page 60 and 61:
C H A P T E R 3 Transcription Arthu
Page 62 and 63:
UNUSUAL MODES OF TRANSCRIPTION IN T
Page 64 and 65:
CLASS I TRANSCRIPTION IN TRYPANOSOM
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
CLASS II TRANSCRIPTION OF PROTEIN C
Page 72 and 73:
SL RNA AND U snRNA GENE TRANSCRIPTI
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
FURTHER READING 65 and switching in
Page 80 and 81:
C H A P T E R 4 Post-transcriptiona
Page 82 and 83:
POST-TRANSCRIPTIONAL REGULATION IN
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
FURTHER READING 87 inhibition, it m
Page 102 and 103:
C H A P T E R 5 Antigenic variation
Page 104 and 105:
ANTIGENIC VARIATION AT THE STRUCTUR
Page 106 and 107:
ANTIGENIC VARIATION AT THE STRUCTUR
Page 108 and 109:
VSG Signal sequence Amino-terminal
Page 110 and 111:
GENETICS OF ANTIGENIC VARIATION 97
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
IMMUNE RESPONSES TO TRYPANOSOME INF
Page 118 and 119:
INNATE RESISTANCE, HUMAN SUSCEPTIBI
Page 120 and 121:
ANTIGENIC VARIATION IN MALARIA 107
Page 122 and 123:
FURTHER READING 109 ACKNOWLEDGEMENT
Page 124 and 125:
C H A P T E R 6 Genetic and genomic
Page 126 and 127:
‘FORWARD’ VS. ‘REVERSE’ GEN
Page 128 and 129:
EXAMPLES OF ‘FORWARD’ GENETIC A
Page 130 and 131:
EXAMPLES OF ‘FORWARD’ GENETIC A
Page 132 and 133:
REVERSE GENETICS AND LEISHMANIA VIR
Page 134 and 135:
VALIDATION OF CANDIDATE VIRULENCE G
Page 136 and 137:
S E C T I O N II BIOCHEMISTRY AND C
Page 138 and 139:
C H A P T E R 7 Energy metabolism P
Page 140 and 141:
SUBCELLULAR ORGANIZATION OF AMITOCH
Page 142 and 143:
CELL MEMBRANE Fructose [b] Glucose
Page 144 and 145:
STEPS OF AMITOCHONDRIATE CORE METAB
Page 146 and 147:
ENZYMATIC DIFFERENCES BETWEEN AMITO
Page 148 and 149:
ACTION OF NITROIMIDAZOLE DRUGS 135
Page 150 and 151:
ENVOI 137 unambiguously reflect the
Page 152 and 153:
FURTHER READING 139 Saavedra-Lira,
Page 154 and 155:
THE EMBDEN-MEYERHOF-PARNAS (EMP) PA
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
WHY DO TRYPANOSOMATIDAE HAVE GLYCOS
Page 166 and 167:
FURTHER READING 153 for use in agri
Page 168:
CARBOHYDRATE METABOLISM 155 as a hu
Page 171 and 172:
158 ENERGY METABOLISM - APICOMPLEXA
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
172 PROTEIN METABOLISM PROTEINS (1)
Page 187 and 188:
174 PROTEIN METABOLISM the C-termin
Page 189 and 190:
176 PROTEIN METABOLISM and also, to
Page 191 and 192:
178 PROTEIN METABOLISM values rangi
Page 193 and 194:
180 PROTEIN METABOLISM of the plasm
Page 195 and 196:
182 PROTEIN METABOLISM in vivo, in
Page 197 and 198:
184 PROTEIN METABOLISM PROLINE Poly
Page 199 and 200:
186 PROTEIN METABOLISM CO 2 Dec-SAM
Page 201 and 202:
188 PROTEIN METABOLISM a cMDH has b
Page 203 and 204:
190 PROTEIN METABOLISM Urea ARGININ
Page 205 and 206:
192 PROTEIN METABOLISM been describ
Page 207 and 208:
194 PROTEIN METABOLISM absence of g
Page 209 and 210:
Page 211 and 212:
198 PURINES AND PYRIMIDINES enable
Page 213 and 214:
200 PURINES AND PYRIMIDINES provide
Page 215 and 216:
202 PURINES AND PYRIMIDINES activit
Page 217 and 218:
204 PURINES AND PYRIMIDINES physiol
Page 219 and 220:
206 PURINES AND PYRIMIDINES Amitoch
Page 221 and 222:
208 PURINES AND PYRIMIDINES their a
Page 223 and 224:
210 PURINES AND PYRIMIDINES FIGURE
Page 225 and 226:
Page 227 and 228:
214 PURINES AND PYRIMIDINES protein
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
220 PURINES AND PYRIMIDINES in Plas
Page 235 and 236:
222 PURINES AND PYRIMIDINES whereas
Page 237 and 238:
Page 239 and 240:
226 TRYPANOSOMATID CARBOHYDRATES AF
Page 241 and 242:
228 TRYPANOSOMATID CARBOHYDRATES In
Page 243 and 244:
230 TRYPANOSOMATID CARBOHYDRATES po
Page 245 and 246:
232 TRYPANOSOMATID CARBOHYDRATES LP
Page 247 and 248:
234 TRYPANOSOMATID CARBOHYDRATES re
Page 249 and 250:
236 TRYPANOSOMATID CARBOHYDRATES sc
Page 251 and 252:
A. sAP COOH [T][T](S/T)(S/T)(S/T)SS
Page 253 and 254:
240 TRYPANOSOMATID CARBOHYDRATES Cr
Page 255 and 256:
242 INTRACELLULAR SIGNALING protein
Page 257 and 258: 244 INTRACELLULAR SIGNALING FIGURE
Page 259 and 260: 246 INTRACELLULAR SIGNALING 212.5 2
Page 261 and 262: 248 INTRACELLULAR SIGNALING cycle.
Page 263 and 264: 250 INTRACELLULAR SIGNALING V-H -A
Page 265 and 266: 252 INTRACELLULAR SIGNALING domain)
Page 267 and 268: 254 INTRACELLULAR SIGNALING the kno
Page 269 and 270: 256 INTRACELLULAR SIGNALING from in
Page 271 and 272: 258 INTRACELLULAR SIGNALING FIGURE
Page 273 and 274: 260 INTRACELLULAR SIGNALING ESAG4 (
Page 275 and 276: 262 INTRACELLULAR SIGNALING and ind
Page 277 and 278: 264 INTRACELLULAR SIGNALING ATPase
Page 279 and 280: 266 INTRACELLULAR SIGNALING G11XG
Page 281 and 282: 268 INTRACELLULAR SIGNALING a diffe
Page 283 and 284: 270 INTRACELLULAR SIGNALING rapid l
Page 285 and 286: 272 INTRACELLULAR SIGNALING cells w
Page 287 and 288: 274 INTRACELLULAR SIGNALING PfPPJ i
Page 289 and 290: 276 INTRACELLULAR SIGNALING is cont
Page 291 and 292: 278 PLASTIDS, MITOCHONDRIA, AND HYD
Page 307: 294 PLASTIDS, MITOCHONDRIA, AND HYD
Page 311 and 312: 298 HELMINTH SURFACES Important exc
Page 313 and 314: 300 HELMINTH SURFACES protease inhi
Page 315 and 316: 302 HELMINTH SURFACES volume, there
Page 317 and 318: 304 HELMINTH SURFACES projecting si
Page 319 and 320: 306 HELMINTH SURFACES schistosome t
Page 321 and 322: 308 HELMINTH SURFACES re-establish
Page 323 and 324: 310 HELMINTH SURFACES hepatic cells
Page 325 and 326: 312 HELMINTH SURFACES lungs. Larvae
Page 327 and 328: 314 HELMINTH SURFACES cuticle, whic
Page 329 and 330: 316 HELMINTH SURFACES cuticle in th
Page 331 and 332: 318 HELMINTH SURFACES mec-8 or sym-
Page 333 and 334: 320 HELMINTH SURFACES current, when
Page 335 and 336: 322 HELMINTH SURFACES The cuticle-h
Page 337 and 338: 324 HELMINTH SURFACES are typically
Page 339 and 340: 326 HELMINTH SURFACES or carrier pr
Page 341 and 342: 328 HELMINTH SURFACES of tyrosine-b
Page 343 and 344: 330 HELMINTH SURFACES blood. The ge
Page 345 and 346: 332 HELMINTH SURFACES Mutations in
Page 347 and 348: 334 HELMINTH SURFACES in the hypode
Page 349 and 350: 336 HELMINTH SURFACES (including H-
Page 351 and 352: 338 HELMINTH SURFACES Blaxter, M.L.
Page 353 and 354: 340 ENERGY METABOLISM IN HELMINTHS
Page 359 and 360:
346 ENERGY METABOLISM IN HELMINTHS
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
360 NEUROTRANSMITTERS CO 2 H NH 2 G
Page 375 and 376:
362 NEUROTRANSMITTERS TABLE 15.1 An
Page 377 and 378:
364 NEUROTRANSMITTERS more arms tha
Page 379 and 380:
366 NEUROTRANSMITTERS the surroundi
Page 381 and 382:
368 NEUROTRANSMITTERS proteins requ
Page 383 and 384:
370 NEUROTRANSMITTERS FIGURE 15.11
Page 385 and 386:
372 NEUROTRANSMITTERS FIGURE 15.13
Page 387 and 388:
374 NEUROTRANSMITTERS sensitivity t
Page 389 and 390:
376 NEUROTRANSMITTERS TABLE 15.3 Cl
Page 391 and 392:
378 NEUROTRANSMITTERS crossed the c
Page 393 and 394:
380 NEUROTRANSMITTERS have been tes
Page 395 and 396:
382 NEUROTRANSMITTERS C-terminals a
Page 397 and 398:
384 NEUROTRANSMITTERS Davis and Str
Page 399 and 400:
386 NEUROTRANSMITTERS Cephalic gang
Page 401 and 402:
388 NEUROTRANSMITTERS myoexcitation
Page 403 and 404:
390 NEUROTRANSMITTERS is phosphoryl
Page 405 and 406:
392 NEUROTRANSMITTERS many other an
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
398 DRUG RESISTANCE of some of the
Page 413 and 414:
400 DRUG RESISTANCE It is now estim
Page 415 and 416:
402 DRUG RESISTANCE is again assume
Page 417 and 418:
404 DRUG RESISTANCE An alternative
Page 419 and 420:
406 DRUG RESISTANCE clinical eviden
Page 421 and 422:
408 DRUG RESISTANCE FIGURE 16.4 Fol
Page 423 and 424:
410 DRUG RESISTANCE Using similar s
Page 425 and 426:
412 DRUG RESISTANCE whether these r
Page 427 and 428:
414 DRUG RESISTANCE FIGURE 16.5 Str
Page 429 and 430:
416 DRUG RESISTANCE FIGURE 16.6 Try
Page 431 and 432:
418 DRUG RESISTANCE has permitted e
Page 433 and 434:
420 DRUG RESISTANCE FIGURE 16.7 Dru
Page 435 and 436:
422 DRUG RESISTANCE near future. Th
Page 437 and 438:
424 DRUG RESISTANCE million new inf
Page 439 and 440:
426 DRUG RESISTANCE some 50 million
Page 441 and 442:
428 DRUG RESISTANCE pharynx, the bo
Page 443 and 444:
430 DRUG RESISTANCE efforts for glo
Page 445 and 446:
432 DRUG RESISTANCE and resistance
Page 447 and 448:
434 MEDICAL IMPLICATIONS TABLE 17.1
Page 449 and 450:
436 MEDICAL IMPLICATIONS TABLE 17.1
Page 451 and 452:
438 MEDICAL IMPLICATIONS transmissi
Page 453 and 454:
440 MEDICAL IMPLICATIONS H 2 C H H
Page 455 and 456:
442 MEDICAL IMPLICATIONS parasites
Page 457 and 458:
444 MEDICAL IMPLICATIONS neuropsych
Page 459 and 460:
446 MEDICAL IMPLICATIONS of toxic f
Page 461 and 462:
448 MEDICAL IMPLICATIONS Future con
Page 463 and 464:
450 MEDICAL IMPLICATIONS Melarsopro
Page 465 and 466:
452 MEDICAL IMPLICATIONS prevention
Page 467 and 468:
454 MEDICAL IMPLICATIONS resulting
Page 469 and 470:
456 MEDICAL IMPLICATIONS for S. ste
Page 471 and 472:
458 MEDICAL IMPLICATIONS are though
Page 473 and 474:
460 MEDICAL IMPLICATIONS FIGURE 17.
Page 475 and 476:
462 MEDICAL IMPLICATIONS Marr, J.J.
Page 477 and 478:
464 INDEX Aldolase, 143 Plasmodium
Page 479 and 480:
466 INDEX Ascofuranone, 143 ASCUT-1
Page 481 and 482:
468 INDEX Cnidarians, RNA trans-spl
Page 483 and 484:
470 INDEX Entamoeba, 125 Ca 2 metab
Page 485 and 486:
472 INDEX Glucose-6-phosphate dehyd
Page 487 and 488:
474 INDEX Ivermectin, 398, 427, 455
Page 489 and 490:
476 INDEX Maduramicin, 412 Major va
Page 491 and 492:
478 INDEX Nitric oxide: neurotransm
Page 493 and 494:
480 INDEX calcium-binding proteins,
Page 495 and 496:
482 INDEX Pyrimidine transport, 200
Page 497 and 498:
484 INDEX Succinate:rhodoquinone ox
Page 499 and 500:
486 INDEX genome, 21 survey sequenc
Page 501:
488 INDEX U small nuclear RNA (snRN
show all

trans

Create successful ePaper yourself

Delete template?

Save as template?